42802-94-8

Basic information

• Product Name: 4-(2-BroMoethyl)Morpholine HydrobroMide
• Synonyms: 4-(2-BroMoethyl)Morpholine HydrobroMide;beta-Morpholinoethyl bromide hydrobromide;Morpholine,4-(2-bromoethyl)-,hydrobromide;2-(4-morpholine)ethyl bromide HBr;Morpholine,4-(2-bromoethyl)-, hydrobromide (1:1);4-(2-BROMOETHYL)MORPHOLINE HBR
• CAS NO: 42802-94-8
• Molecular Formula: BrH*C₆H₁₂BrNO
• Molecular Weight: 275
• Mol File: 42802-94-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 222-224℃ (methanol )
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-(2-BroMoethyl)Morpholine HydrobroMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-BroMoethyl)Morpholine HydrobroMide(42802-94-8)
• EPA Substance Registry System: 4-(2-BroMoethyl)Morpholine HydrobroMide(42802-94-8)

Safety Data

• Hazardous Substances Data: 42802-94-8(Hazardous Substances Data)

Usage

General Description

4-(2-BroMoethyl)Morpholine HydrobroMide is a chemical compound that falls into the class of morpholines, which are organic compounds containing a morpholine ring. As such, it presents a variety of potential uses in both scientific research and industry. It may be utilized in the production of pharmaceuticals and other chemical products, as its morpholine structure implies potential bioactivity. Furthermore, it also sees use in the synthesis of more complex chemicals. The exact properties of this compound, such as its toxicity, safety concerns, and environmental impact, may heavily rely upon the specifics of its application and transformation in chemical reactions.

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 

Downstream Products

• 1152961-27-7 1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-ylamine 
• 864754-18-7 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)morpholine 
• 1951483-29-6 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one 

Relevant articles and documents

COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER

The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin- 4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof, preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).

Self-assembly of pseudo-rotaxane and rotaxane complexes using an electrostatic slippage approach

The protonation of a cyclic tertiary amine, integrated into the structure of a dumbbell-shaped guest molecule, accelerates the sliding of the guest through the cavity of a crown ether macrocycle to yield a stable pseudo-rotaxane complex. The use of an amine with the appropriate ring size followed by a proton transfer reaction leads to the formation of an interlocked rotaxane species.